NetScientific hires another specialist for portfolio firm

(MENAFN- ProactiveInvestors)Biomedical group NetScientific (LON:NSCI) hired Lawrence Cohen as chief executive of its portfolio company molecular diagnostics group Glycotest from January 4 to accelerate the commercialisation of its novel non-invasive blood tests.   Glycotest is commercialising testing services which reduce mortality and increases survival for patients at risk of liver cancers and fibrosis-cirrhosis.    Cohen has over three decades' experience in the medical device and diagnostics sector with his most recent role  as  chief exeuctive of  Exalenz Bioscience a medical device company for the diagnosis and management of digestive tract and liver diseases.     He was also chief executive  of SenGenix chief executive of Hemosense and president of International Technidyne Corp. which grew three times under his leadership.    Francois Martelet NetScientific chief executive said: "Larry Cohen is a seasoned executive in the world of diagnostics who will be instrumental in driving the delivery of Glycotest's novel tests.    "Our focus as a group is to move our portfolio companies to commercialisation. Larry's appointment follows on from our recent appointment of Gene Walther as CEO of Vortex BioSciences both will play a crucial part in our Diagnostics franchise once they start in their roles on 4 January 2016."